Altered extrafocal iomazenil activity in mesial temporal lobe epilepsy

Koichi Hosomi1, Haruhiko Kishima, Satoru Oshino

  • 1Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Epilepsy Research
|July 24, 2012
PubMed

Insights

Mesial temporal lobe epilepsy (MTLE) involves more than just the temporal lobe. Iomazenil (IMZ) SPECT imaging reveals decreased IMZ activity in extratemporal regions, suggesting wider brain dysfunction in MTLE patients.

Area of Science:

  • Neurology
  • Neuroimaging
  • Epilepsy Research

Background:

  • Mesial temporal lobe epilepsy (MTLE) is a common epilepsy syndrome.
  • The extent of brain regions affected in MTLE is not fully understood.
  • Investigating extratemporal involvement is crucial for understanding MTLE pathophysiology.

Purpose of the Study:

  • To explore the involvement of extratemporal regions in MTLE.
  • To identify abnormalities in iomazenil (IMZ) distribution in MTLE patients.
  • To assess interhemispheric asymmetry in IMZ binding using SPECT imaging.

Main Methods:

  • Retrospective analysis of 14 MTLE patients with good surgical outcomes.
  • Utilized iomazenil (IMZ) SPECT imaging to assess brain activity.
  • Applied voxel-based (VB) and volume-of-interest (VOI) analyses to compare IMZ binding between hemispheres.

Main Results:

  • VB analysis revealed decreased IMZ binding in ipsilateral anterior temporal lobe and extratemporal regions (insula, putamen, medial occipital lobe).
  • VOI analysis confirmed significant decreases in ipsilateral parahippocampal gyrus, amygdala, putamen, lateral temporal lobe, and lateral occipital lobe.
  • Demonstrated significant interhemispheric asymmetry in IMZ binding.

Conclusions:

  • Decreased iomazenil binding in MTLE extends beyond the mesial temporal lobe to ipsilateral extratemporal areas.
  • Suggests widespread dysfunctional iomazenil activity in the brain of MTLE patients.
  • Highlights the importance of considering extratemporal involvement in MTLE.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...